DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS 
Targeted vitamin D3 supplementation cut second heart attack risk by more than half in patients with prior MI, using individualized dosing to maintain 40 ng/mL levels. The 630-patient TARGET-D trial reduced repeat MI from 7.9% to 3.8% with personalized dose adjustment.
🔬 CLINICAL CONSIDERATIONS
- 87% of post-MI patients had low vitamin D at enrollment (average 27 ng/mL), suggesting widespread deficiency in cardiac populations requiring screening
- Individualized dosing approach (starting 5,000 IU for 60%) with ongoing monitoring proved more effective than fixed-dose protocols from previous failed trials
- Benefit specific to recurrent MI prevention—no significant difference in overall cardiac events including death, heart failure hospitalization, or stroke outcomes
- Results presented at AHA 2025 but not yet peer-reviewed; larger confirmatory trials needed before changing practice standards
🎯 PRACTICE APPLICATIONS
- Screen vitamin D levels in all post-MI patients during hospital admission or follow-up
- Target 40 ng/mL vitamin D levels with individualized supplementation rather than fixed dosing
- Monitor levels every 3-6 months to maintain optimal range and adjust doses accordingly
- Counsel patients that vitamin D supplementation complements but doesn’t replace proven cardiac therapies
More on MI/Heart Attacks
